title: Positron emission tomography with 11C CGP-12177 to assess beta-adrenergic receptor concentration in idiopathic dilated cardiomyopathy.
abstract: BACKGROUND
  Positron emission tomography (PET) with 11C-labeled CGP-12177 (CGP) has been shown to have the potential to noninvasively measure beta-adrenergic receptor concentration in dog heart. The present study was undertaken to evaluate the clinical value of this technique.
  
  
  RESULTS
  Eight normal subjects and 10 patients with heart failure related to an idiopathic cardiomyopathy were studied. Estimation of beta-receptor concentration was based on a graphic method applied on myocardial PET time-concentration curves obtained after an intravenous injection of 11C-CGP followed 30 minutes later by a coinjection of labeled and unlabeled CGP. The clinical tolerance of these injections was good. Left ventricular concentration of beta-receptors was decreased in patients compared with controls (3.12 +/- 0.51 versus 6.60 +/- 1.18 pmol/mL, respectively; p < 0.001). This 53% decrease agrees with previous in vitro data. In eight of the 10 patients, the beta-receptor concentration obtained from PET was compared with the beta-receptor density determined on left ventricular endomyocardial biopsy samples by in vitro binding technique using 3H-CGP-12177. Results obtained with both techniques were correlated (r = 0.79, p = 0.019). Moreover, decreased beta-receptor concentration correlated with the beta-contractile responsiveness to intracoronary dobutamine infusion (r = 0.83, p = 0.003), indicating a direct link between changes in the receptor number and its biological function.
  
  
  CONCLUSIONS
  PET appears to be a safe and reliable method of assessing in vivo changes in the number of left ventricular beta-adrenergic receptor sites of patients with idiopathic cardiomyopathy.
authors.affiliation: Service Hospitalier Frédéric Joliot, CEA, Orsay, France.
authors.forename: P
authors.initials: P
authors.lastname: Merlet
authors.forename: J
authors.initials: J
authors.lastname: Delforge
authors.forename: A
authors.initials: A
authors.lastname: Syrota
authors.forename: E
authors.initials: E
authors.lastname: Angevin
authors.forename: B
authors.initials: B
authors.lastname: Mazière
authors.forename: C
authors.initials: C
authors.lastname: Crouzel
authors.forename: H
authors.initials: H
authors.lastname: Valette
authors.forename: D
authors.initials: D
authors.lastname: Loisance
authors.forename: A
authors.initials: A
authors.lastname: Castaigne
authors.forename: J L
authors.initials: JL
authors.lastname: Randé
mesh_terms: D000319:Adrenergic beta-Antagonists; D002250:Carbon Radioisotopes; D002311:Cardiomyopathy, Dilated / Q000000981:diagnostic imaging*; D004280:Dobutamine; D005260:Female; D006321:Heart / Q000000981:diagnostic imaging* / Q000294:innervation; D006801:Humans; D008297:Male; D008875:Middle Aged; D009206:Myocardium / Q000378:metabolism; D009638:Norepinephrine / Q000097:blood; D011412:Propanolamines; D011943:Receptors, Adrenergic, beta / Q000032:analysis*; D014055:Tomography, Emission-Computed; D016277:Ventricular Function, Left / Q000502:physiology
chemical_list: D000319:Adrenergic beta-Antagonists; D002250:Carbon Radioisotopes; D011412:Propanolamines; D011943:Receptors, Adrenergic, beta; D004280:Dobutamine; C033394:CGP 12177; D009638:Norepinephrine